MX2021003609A - Molecula de union a antigeno que comprende una region variable de anticuerpo alterada. - Google Patents

Molecula de union a antigeno que comprende una region variable de anticuerpo alterada.

Info

Publication number
MX2021003609A
MX2021003609A MX2021003609A MX2021003609A MX2021003609A MX 2021003609 A MX2021003609 A MX 2021003609A MX 2021003609 A MX2021003609 A MX 2021003609A MX 2021003609 A MX2021003609 A MX 2021003609A MX 2021003609 A MX2021003609 A MX 2021003609A
Authority
MX
Mexico
Prior art keywords
cells
binding molecule
antigen
variable region
antibody variable
Prior art date
Application number
MX2021003609A
Other languages
English (en)
Inventor
Hirotake Shiraiwa
Tomoyuki Igawa
Shu Feng
Shu Wen Samantha Ho
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2021003609A publication Critical patent/MX2021003609A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona una molécula de unión a antígeno capaz de unirse a varios antígenos diferentes (por ejemplo, CD3 en células T y CD137 en células T, células NK, células DC y/o similares), pero que no reticula inespecíficamente dos o más células inmunitarias tal como células T. Esa molécula de unión a antígeno multiespecífica es capaz de modular y/o activar una respuesta inmune mientras evita la reticulación entre diferentes células (por ejemplo, diferentes células T) resultante de la unión de una molécula de unión a antígeno multiespecífica convencional a antígenos expresados en las diferentes células, que se considera responsable de reacciones adversas cuando la molécula de unión a antígeno multiespecífica se usa como fármaco.
MX2021003609A 2018-09-28 2019-09-27 Molecula de union a antigeno que comprende una region variable de anticuerpo alterada. MX2021003609A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018185120 2018-09-28
PCT/JP2019/038087 WO2020067399A1 (en) 2018-09-28 2019-09-27 Antigen-binding molecule comprising altered antibody variable region

Publications (1)

Publication Number Publication Date
MX2021003609A true MX2021003609A (es) 2021-05-28

Family

ID=69950667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003609A MX2021003609A (es) 2018-09-28 2019-09-27 Molecula de union a antigeno que comprende una region variable de anticuerpo alterada.

Country Status (11)

Country Link
US (1) US20220112296A1 (es)
EP (1) EP3856789A4 (es)
JP (1) JP2022501325A (es)
KR (1) KR20210068061A (es)
CN (1) CN113260634A (es)
AU (1) AU2019347408A1 (es)
BR (1) BR112021005472A2 (es)
CA (1) CA3113594A1 (es)
MX (1) MX2021003609A (es)
SG (1) SG11202102882YA (es)
WO (1) WO2020067399A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113307873A (zh) 2013-11-11 2021-08-27 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
TWI740809B (zh) 2014-11-11 2021-10-01 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
MX2022012092A (es) * 2020-03-31 2022-10-13 Chugai Pharmaceutical Co Ltd Moleculas de union al antigeno multiespecificas dirigidas a claudina-6 y sus usos.
SG11202105302PA (en) 2020-03-31 2021-11-29 Chugai Pharmaceutical Co Ltd Dll3-targeting multispecific antigen-binding molecules and uses thereof
IL296802A (en) * 2020-03-31 2022-11-01 Chugai Pharmaceutical Co Ltd A method for the production of multispecific antigen binding molecules
WO2021200896A1 (en) * 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Immune activating multispecific antigen-binding molecules and uses thereof
WO2023053272A1 (en) * 2021-09-29 2023-04-06 Chugai Seiyaku Kabushiki Kaisha Uses of dll3-targeting multispecific antigen-binding molecules
JP7470760B2 (ja) * 2021-09-29 2024-04-18 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
WO2023053282A1 (ja) * 2021-09-29 2023-04-06 中外製薬株式会社 がんの治療に用いるための細胞傷害誘導治療剤
WO2023154533A2 (en) * 2022-02-14 2023-08-17 Twist Bioscience Corporation Combinatorial dna assembly for multispecific antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
KR101940059B1 (ko) * 2008-12-19 2019-01-18 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
WO2012064792A2 (en) * 2010-11-09 2012-05-18 Altimab Therapeutics, Inc. Protein complexes for antigen binding and methods of use
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN113307873A (zh) * 2013-11-11 2021-08-27 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
JP2017509337A (ja) * 2014-03-12 2017-04-06 ノバルティス アーゲー イムノコンジュゲートを作製する抗体を修飾するための特定部位
US20170274072A1 (en) * 2014-03-26 2017-09-28 Tohoku University Bispecific antibody targeting human epidermal growth factor receptor
NZ724710A (en) 2014-04-07 2024-02-23 Chugai Pharmaceutical Co Ltd Immunoactivating antigen-binding molecule
EP3305322A4 (en) * 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
TW201938194A (zh) * 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
AU2019315226A1 (en) * 2018-08-03 2021-03-18 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing two antigen-binding domains that are linked to each other

Also Published As

Publication number Publication date
WO2020067399A1 (en) 2020-04-02
AU2019347408A1 (en) 2021-04-15
JP2022501325A (ja) 2022-01-06
EP3856789A1 (en) 2021-08-04
KR20210068061A (ko) 2021-06-08
CA3113594A1 (en) 2020-04-02
SG11202102882YA (en) 2021-04-29
CN113260634A (zh) 2021-08-13
BR112021005472A2 (pt) 2021-06-15
EP3856789A4 (en) 2022-08-17
US20220112296A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
MX2021003609A (es) Molecula de union a antigeno que comprende una region variable de anticuerpo alterada.
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
WO2017055398A3 (en) Bispecific antibodies specific for a costimulatory tnf receptor
WO2016145085A3 (en) Cd27 agonists
MY188362A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PH12018501778A1 (en) Antibodies to tigit
EP3765522A4 (en) ANTI-CLAUDIN 18.2 ANTIBODIES
EP3720963A4 (en) ANTIGEN BINDING MOLECULE INCLUDING A VARIABLE REGION OF MODIFIED ANTIBODIES BINDING TO CD3 AND CD137
WO2018128662A3 (en) Large scale optical phased array
SG11202100987RA (en) Antibody constructs for cldn18.2 and cd3
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
PH12021550662A1 (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
WO2016205520A8 (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
WO2019236749A3 (en) Methods and applications of protein identification
WO2019178364A3 (en) Multifunctional molecules and uses thereof
EP3773676A4 (en) PROTEINS THAT BIND NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS
WO2015184001A8 (en) Anti-tnf-alpha glycoantibodies and uses thereof
WO2019099597A3 (en) Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
WO2017156495A8 (en) Compounds and methods for modulating bruton's tyrosine kinase
WO2019242632A8 (en) Engineered cells and uses thereof
MX2020006818A (es) Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos.
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
WO2019070648A3 (en) Reactor systems
WO2018069871A3 (en) Anti-kras binding proteins